Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
Launched by ASTRAZENECA · Apr 13, 2010
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with confirmed type 2 diabetes for at least 1 year and treated with metformin as a single treatment or in combination with one other oral anti diabetic for at least 2 months prior to screening.
- • Body mass index between ≥19 and ≤42 kg/m2.
- • Haemoglobin (Hb) A1c ≥6.5% and ≤9.5% at enrolment.
- Exclusion Criteria:
- • History of cardiovascular disease, eg, left ventricular hypertrophy, uncontrolled hypertension, paroxysmal or persistent cardiac arrhythmia or ischemic heart disease.
- • Systolic blood pressure \>160 mmHg or diastolic blood pressure \>95 mmHg at screening
- • Use of amiodarone within 3 months prior to screening and the use of potent CYP450 inhibitors
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chula Vista, California, United States
Patients applied
Trial Officials
Stanko Skrtic
Study Director
AstraZeneca
Christoph Kapitza
Principal Investigator
Profil Institut für Stoffwechselforschung GmbH
Mirjana Kujacic
Study Chair
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials